Abilify Maintena (aripiprazole) will be another intramuscular long-acting atypical antipsychotic option

May 2014

Abilify Maintena (aripiprazole) will be another intramuscular long-acting atypical antipsychotic option in Canada.

It's approved for stable adults with schizophrenia.

Help choose a long-acting injectable based on their convenience, cost, and tolerability.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Geriatrics promoting appropriate use of high-risk meds in the elderly
Testosterone The debate about treating "low T" in older men will heat up
Vaccines which travellers should get typhoid vaccine and which one to choose
Cardiology more focus on optimizing medication use after hospital discharge for a heart attack
Respiratory & Allergy when and how to use spacers with metered-dose inhalers (MDIs)
Diabetes Which meds can actually increase the risk of developing diabetes
Antithrombotics The newer anticoagulants will be used more to prevent stroke due to atrial fibrillation
Women's Health treatment of polycystic ovary syndrome (PCOS)
Antipsychotics Abilify Maintena (aripiprazole) will be another intramuscular long-acting atypical antipsychotic option
Supplements Patients are asking if multivitamins are beneficial